BiotechTube
StratifAI

StratifAI

Munich, Germany· Est.
stratifai.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

StratifAI is a Munich-based, privately-held diagnostics company developing an AI-powered biomarker discovery and validation platform for precision oncology. Founded in 2018, its flagship Polaris™ platform uses weakly supervised deep learning on multimodal data to create predictive models from routine pathology slides. The company is currently advancing its first diagnostic, Polaris™ Breast, through regulatory validation in the EU and US, backed by €14M in funding and strategic partnerships with leading oncology institutes.

Oncology

Technology Platform

Polaris™: An AI-powered, multimodal biomarker discovery platform that uses weakly supervised deep learning on whole-slide histology images integrated with RNASeq and patient outcome data to identify predictive spatial biology signatures.

Opportunities

The global shift towards precision oncology creates massive demand for cost-effective, scalable diagnostic tools that improve risk stratification.
Using standard histology slides as input allows for rapid integration into existing pathology workflows worldwide.
Success with Polaris™ Breast provides a template to expand the platform into dozens of other cancer types, each representing a multi-billion dollar diagnostic market.

Risk Factors

The primary risks are regulatory, as obtaining approval for a novel AI-based SaMD is complex and uncertain.
Clinical adoption and securing reimbursement from payers are significant subsequent hurdles.
The company also faces intense competition in the rapidly evolving AI pathology space and must ensure its models generalize across diverse patient populations and clinical settings.

Competitive Landscape

StratifAI competes in the computational pathology/AI diagnostics space against companies like PathAI, Paige.AI, and Owkin, which also develop AI models for pathology image analysis. Its specific focus on multimodal integration (histology + RNASeq + outcomes) and an end-to-end weakly supervised approach are key differentiators. In breast cancer, it faces competition from established genomic tests like Oncotype DX and MammaPrint, against which it must prove clinical utility and cost-effectiveness.

More companies in Diagnostics & Precision Medicine →More companies in Germany →